107 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
University of Minnesota
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
Genomics Institute of Novartis Research Foundation
Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.
Glaxosmithkline
Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.
Sumitomo Dainippon Pharma
Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
Dainippon Sumitomo Pharma
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
TBA
Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
University of Kansas
Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.
University of Kansas
Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.
University of Kansas
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Pfizer
Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7.
University of Kansas
Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.
University of Kansas
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
Dainippon Sumitomo Pharma
Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.
University of Kansas
Synthesis and Optimization of 1-Substituted Imidazo[4,5-
Binghamton University School of Pharmacy and Pharmaceutical Sciences
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases.
Novartis Institutes for Biomedical Research
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.
Bristol Myers Squibb
Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology.
Bristol-Myers Squibb Research & Development
Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.
West China Hospital
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates.
Zymeworks
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
Smith, Gambrell & Russell
Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.
Panjab University
If small molecules immunotherapy comes, can the prime be far behind?
Zhejiang University
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
University of Montpellier
Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.
Csir-Indian Institute of Chemical Biology
Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
University of Minnesota
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).
Biocon Bristol Myers Squibb Research Center (Bbrc)
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
Csir-Indian Institute of Chemical Biology
Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators.
University of Ljubljana
Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.
Roche Innovation Center Shanghai
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an
Novartis Institutes For Biomedical Research
Spiro(isobenzofuranazetidine) Compounds for Treating Autoimmune Diseases.
Smith, Gambrell & Russell
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9.
Csir-Indian Institute of Chemical Biology
Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Beijing Advanced Innovation Center For Human Brain Protection
Novel Triazatricycle Compounds for Treating Autoimmune Diseases.
Smith, Gambrell & Russell
Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.
Smith, Gambrell & Russell
Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.
Csir-Indian Institute of Chemical Biology
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
University of Kansas
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
Genomics Institute of The Novartis Research Foundation
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Gilead Sciences
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
Astrazeneca
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
University of Montana
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Princ
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute of The Novartis Research Foundation
Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands.
Kagoshima University
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
University of Kansas
A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.
Csir-Indian Institute of Chemical Biology
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
University of Colorado Boulder
Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
University of Ljubljana
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
University of Minnesota
Activity-guided development of potent and selective toll-like receptor 9 antagonists.
Csir-Indian Institute of Chemical Biology
Toll-like Receptors for the Treatment of Autoimmune, Inflammation, and Infectious Diseases.
Usona Institute
Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties.
University of Colorado
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
University of Minnesota
Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism.
Csir-Indian Institute of Chemical Biology
Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
Janssen Pharmaceutica
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University of Colorado Boulder
3-ARYLOXYL-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND AND USE THEREOF
Shanghai Leado Pharmatech Co.
3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
Janssen Pharmaceutica
NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Shanghai Longwood Biopharmaceuticals
JAK kinase inhibitor compounds for treatment of respiratory disease
Theravance Biopharma R&D Ip
Compounds as neuronal histamine receptor-3 antagonists and uses thereof
Xw Laboratories
Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
Merck Sharp & Dohme
Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
Galderma Research & Development
6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
Bristol-Myers Squibb
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Enanta Pharmaceuticals
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
Loxo Oncology
Synthesis and biological evaluation of novel series of aminopyrimidine derivatives as urease inhibitors and antimicrobial agents.
Solapur University
Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
Ono Pharmaceutical
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
Reviva Pharmaceuticals
Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.
Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof
Japan Tobacco